These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 35674998)

  • 21. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Breast Cancer Risk Assessment for
    Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
    JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.
    Rudd MF; Sellick GS; Webb EL; Catovsky D; Houlston RS
    Blood; 2006 Jul; 108(2):638-44. PubMed ID: 16574953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
    Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
    JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical
    Borja NA; Silva-Smith R; Huang M; Parekh DJ; Sussman D; Tekin M
    Front Oncol; 2023; 13():1068110. PubMed ID: 36865800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
    Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
    Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
    Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
    Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
    Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
    Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
    Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
    Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D
    Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline
    Bazinet A; Heath J; Chong AS; Simo-Cheyou ER; Worme S; Rivera Polo B; Foulkes WD; Caplan S; Johnson NA; Orthwein A; Mercier FE
    Cold Spring Harb Mol Case Stud; 2021 Jun; 7(3):. PubMed ID: 33986034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with
    Ipe A; Angiolillo A; Jacobsohn D; Cheng J; Bornhorst M; Turner J; Vatsayan A
    Front Pediatr; 2023; 11():1067131. PubMed ID: 36937957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
    Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
    Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.
    Fencer MG; Krupa KA; Bleich GC; Grumet S; Eladoumikdachi FG; Kumar S; Kowzun MJ; Potdevin LB
    Clin Breast Cancer; 2023 Jun; 23(4):e194-e199. PubMed ID: 36966080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.
    Wójcicka A; Czetwertyńska M; Świerniak M; Długosińska J; Maciąg M; Czajka A; Dymecka K; Kubiak A; Kot A; Płoski R; de la Chapelle A; Jażdżewski K
    Genes Chromosomes Cancer; 2014 Jun; 53(6):516-23. PubMed ID: 24599715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.